Page 138 - 《中国药房》2023年21期

patients with hypertrophic cardiomyopathy[J]. PLoS One， of mavacamten in symptomatic patients with nonobstruc‐
2017，12（6）：e0180064. tive hypertrophic cardiomyopathy[J]. J Am Coll Cardiol，
[11] TOEPFER C N，WAKIMOTO H，GARFINKEL A C， 2020，75（21）：2649-2660.
et al. Hypertrophic cardiomyopathy mutations in MYBPC3 [23] OLIVOTTO I，OREZIAK A，BARRIALES-VILLA R，
dysregulate myosin[J]. Sci Transl Med，2019，11（476）： et al. Mavacamten for treatment of symptomatic obstruc‐
eaat1199. tive hypertrophic cardiomyopathy（EXPLORER-HCM）：a
[12] OSLOB J，ANDERSON R，AUBELE D，et al. Pyrimidine- randomised，double-blind，placebo-controlled，phase 3 trial
dione compounds：US20210346379[P]. 2021-11-11. [J]. Lancet，2020，396（10253）：759-769.
[13] SPOLADORE R，MARON M S，D’AMATO R，et al. [24] RADER F，CHOUDHURY L，SABERI S. Updated cumu‐
Pharmacological treatment options for hypertrophic car‐ lative results of treatment with mavacamten from the
diomyopathy：high time for evidence[J]. Eur Heart J， EXPLORER-LTE cohort of the MAVA-LTE study in pa‐
2012，33（14）：1724-1733. tients with obstructive hypertrophic cardiomyopathy [EB/
[14] ZAMPIERI M，ARGIRÒ A，MARCHI A，et al. Mavacam‐ OL].（2022-04-03）[2023-04-01]. http：//news. sohu. com/a/
ten，a novel therapeutic strategy for obstructive hypertro‐ 535108979_121124549.
phic cardiomyopathy[J]. Curr Cardiol Rep， 2021， [25] DESAI M Y，OWENS A，GESKE J B，et al. Myosin inhi‐
23（7）：79. bition in patients with obstructive hypertrophic cardio-
[15] HARTMAN J J，HWEE D T，WANG J Y，et al. Characte- myopathy referred for septal reduction therapy[J]. J Am
rization of the cardiac myosin inhibitor CK-3773274：a po‐ Coll Cardiol，2022，80（2）：95-108.
tential therapeutic approach for hypertrophic cardiomyopa‐ [26] ARGIRÒ A，ZAMPIERI M，BERTEOTTI M，et al.
thy[J]. Biophys J，2020，118（3）：596a. Emerging medical treatment for hypertrophic cardiomyo-
[16] AWINDA P O，BISHAW Y，WATANABE M，et al. Ef‐ pathy[J]. J Clin Med，2021，10（5）：951.
fects of mavacamten on Ca sensitivity of contraction as [27] CHUANG C，COLLIBEE S，ASHCRAFT L，et al. Dis‐
2+
sarcomere length varied in human myocardium[J]. Br J covery of aficamten（CK-274），a next-generation cardiac
Pharmacol，2020，177（24）：5609-5621. myosin inhibitor for the treatment of hypertrophic cardio‐
[17] US FDA. DA approves new drug to improve heart func‐ myopathy[J]. J Med Chem，2021，64（19）：14142-14152.
tion in adults with rare heart condition[EB/OL].（2022-04- [28] MALIK F I，ROBERTSON L A，ARMAS D R，et al. A
29）[2023-04-01]. https：//www.fda.gov/drugs/news-events- phase 1 dose-escalation study of the cardiac myosin inhibi‐
human-drugs/fda-approves-new-drug-improve-heart-func- tor aficamten in healthy participants[J]. JACC Basic
tion-adults-rare-heart-condition. Transl Sci，2022，7（8）：763-775.
[18] 魏宇，郭春. Mavacamten（camzyos）[J]. 中国药物化学杂 [29] MARON M S，MASRI A，CHOUDHURY L，et al. Phase
志，2022，32（12）：980. 2 study of aficamten in patients with obstructive hypertro‐
WEI Y，GUO C. Mavacamten（camzyos）[J]. Chin J Med phic cardiomyopathy[J]. J Am Coll Cardiol，2023，81（1）：
Chem，2022，32（12）：980. 34-45.
[19] GRILLO M P，ERVE J C L，DICK R，et al. In vitro and in [30] MCKEOWN L. REDWOOD-HCM OLE：aficamten im‐
vivo pharmacokinetic characterization of mavacamten，a proves patient-measured health status[EB/OL].（2022-10-
first-in-class small molecule allosteric modulator of beta 07）[2023-04-01].https：//www.163.com/dy/article/HJLMQDN-
cardiac myosin[J]. Xenobiotica，2019，49（6）：718-733. 9053438SI.html.
[20] GREEN E M，WAKIMOTO H，ANDERSON R L，et al. A [31] Cytokinetics Incorporated.Cytokinetics announces start of
small-molecule inhibitor of sarcomere contractility sup‐ SEQUOIA-HCM，a phase 3 clinical trial of aficamten in
presses hypertrophic cardiomyopathy in mice[J]. Science， patients with symptomatic obstructive hypertrophic cardio‐
2016，351（6273）：617-621. myopathy[EB/OL].（2022-02-23）[2023-04-01]. https：//ir.
[21] HEITNER S B，JACOBY D，LESTER S J，et al. cytokinetics. com/news-releases/news-release-details/cyto-
Mavacamten treatment for obstructive hypertrophic car‐ kinetics-announces-start-sequoia-hcm-phase-3-clinical-
diomyopathy：a clinical trial[J]. Ann Intern Med，2019， trial.
170（11）：741-748. （收稿日期：2023-04-07 修回日期：2023-09-25）
[22] HO C Y，MEALIFFE M E，BACH R G，et al. Evaluation （编辑：邹丽娟）

· 2688 · China Pharmacy 2023 Vol. 34 No. 21 中国药房 2023年第34卷第21期